CTX — Crescita Therapeutics Income Statement
0.000.00%
Last trade - 00:00
- CA$11.64m
- CA$3.67m
- CA$17.52m
- 63
- 62
- 49
- 59
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 22.3 | 15.6 | 16.8 | 23.5 | 17.5 |
Cost of Revenue | |||||
Gross Profit | 16.5 | 11 | 9.69 | 13.2 | 10.4 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 19 | 15.3 | 17.5 | 22.9 | 19.1 |
Operating Profit | 3.29 | 0.344 | -0.773 | 0.631 | -1.53 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 3.18 | 0.52 | -1.01 | 0.404 | -1.53 |
Provision for Income Taxes | |||||
Net Income After Taxes | 1.85 | 0.037 | -1.1 | 0.862 | -1.99 |
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | 1.85 | 0.037 | -1.1 | 0.862 | -1.99 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 1.85 | 0.037 | -1.1 | 0.862 | -1.99 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.115 | 0.009 | -0.088 | 0.041 | -0.098 |